Neuromuscular Blockade in the Intensive Care Unit

ABSTRACT

Neuromuscular blocking agents (NMBA) are frequently utilized in the ICU, primarily to facilitate mechanical ventilation. An ideal NMBA is nondepolarizing, has no propensity to accumulate, is easily titrated, has a rapid onset and offset, does not rely on organ function for metabolism, and has no toxic or active metabolites. Current NMBAs are classified as aminosteroids or benzylisoquinoliniums and have different features, but none are ideal. Selection of the best NMBA is determined by individual patient characteristics. Proper use of these agents includes a comprehensive plan to manage all aspects of care affected by NMBA, as well as monitoring of clinical effect and degree of neuromuscular blockade via periodic peripheral nerve stimulation. There are well-recognized complications of NMBA, including prolonged drug effect and acute quadriplegic myopathy. The latter condition can result in prolonged rehabilitation. The use of an NMBA can be essential for the successful outcome from critical illness; however, cautious use of these agents with a structured approach to minimize complications is urged.

KEYWORD

Neuromuscular blocking agent - peripheral nerve stimulation - prolonged paralysis

REFERENCES

• 1 Martyr d' Anghera P. (1516) DeOrbe Novo.  English Translation by MacNutt FA New York: Putnam; 1912
• 2 Brodie B C. Experiments and observations on different modes in which death is produced by certain vegetable poisons.  Phil Trans R Soc London. 1811;  194-195
• 3 Gill R C. Curari, the flying death.  Natural History. 1935;  36 279-286
• 4 Feldman S. Neuromuscular Block.  Oxford: Reed Educational and Professional Publishing, Ltd. 1996: 1-6
• 5 Hansen-Flaschen J H, Brazinsky S, Basile C, Lanken P N. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure: a national survey.  JAMA . 1991;  266 2870-2875
• 6 Christensen B V, Thunedborg L P. Use of sedatives, analgesics and neuromuscular blocking agents in Danish ICUs 1996/97: a national survey.  Intensive Care Med . 1999;  25 186-191
• 7 Magarey J M. Sedation of adult critically ill ventilated patients in intensive care units: a national survey.  Aust Crit Care . 1997;  10 90-93
• 8 Dasta J F, Fuhrman T M, McCandles C. Patterns of prescribing and administering drugs for agitation and pain in patients in a surgical intensive care unit.  Crit Care Med . 1994;  22 974-980
• 9 Prielipp R C, Coursin D B, Wood K E, Murray M J. Complications associated with sedative and neuromuscular blocking drugs in critically ill patients.  Crit Care Clin . 1995;  11 983-1003
• 10 Strange C, Vaughan L, Franklin C, Johnson J. Comparison of train-of-four and best clinical assessment during continuous paralysis.  Am J Respir Crit Care Med . 1997;  156 1556-1561
• 11 Rudis M I, Sikora C A, Angus E. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients.  Crit Care Med . 1997;  25 575-583
• 12 Mascia M F, Koch M, Medicis J J. Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care.  Crit Care Med . 2000;  28 2300-2306
• 13 Appadu B L, Greiff J M, Thompson J P. Postal survey on the long-term use of neuromuscular block in the intensive care.  Intensive Care Med . 1996;  22 862-866
• 14 Shapiro B A, Warren J, Egol A B. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of Critical Care Medicine.  Crit Care Med . 1995;  23 1601-1605
• 15 Kleinpell R, Bedrosian C, McCormick L, Kremer M, Bujalski L, Bronsted R. Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU.  Am J Crit Care . 1996;  5 449-454
• 16 Klessig H T, Geiger H J, Murray M J, Coursin D B. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants.  Crit Care Med . 1992;  20 1341-1345
• 17 Bevan D R, Devan J C, Donati F. Muscle relaxants in clincal anesthesia. Chicago, Year Book Medical Publishers 1988
• 18 Stoelting R, Miller R. Basics of Anesthesia.  Philadelphia: Churchill Livingstone 1994: 83-94
• 19 Bowman W C. Pharmacology of neuromuscular function. 2nd ed. London: Wright; 1990
• 20 Taylor P. Are neuromuscular blocking agents more efficacious in Paris?.  Anesthesiology . 1985;  63 1-3
• 21 Changeux J P. The nicotineic acetylcholine receptor: an allosteric protein prototype of ligand-gated ion channels.  Trends Pharm Sci . 1900;  11 485
• 22 Waud D R. The nature of ``depolarization block''.  Anesthesiology . 1968;  29 1014
• 23 Sokoll M D, Gergis S D. Antibiotics and neuromuscular function.  Anesthesiology . 1981;  55 148-159
• 24 Bevan D R, Donati F. Muscle relaxants. In: Barash P, Cullen B, Stoelting R, eds. Clinical Anesthesia Philadelphia: JB Lippincott 1992: 481-484
• 25 Ducharme J, Donati F. Pharmacokinetics and pharmacodynamics of steroid muscle relaxants. In: Partridge B, ed. Anesth Clinics N Am Philadelphia: WB Saunders 1993: 11:283-285
• 26 Bowman W C. Nonrelaxant properties of neuromuscular blocking drugs.  Br J Anesth . 1982;  54 147
• 27 Basta S J. Modulation of histamine release by neuromuscular blocking drugs.  Curr Opin Anaestheiol . 1992;  5 572-576
• 28 Matthey P, Wang P, Finegan B A, Donnelly M. Rocuronium anaphylaxis and multiple neuromuscular blocking drug sensitivities.  Can J Anaesth . 2000;  47 890-893
• 29 Pollard B T. Neuromuscular blocking agents in specific clinical situations. In: Pollard BT, ed. Applied Neuromuscular Pharmacology Oxford: Oxford University Press; 1994
• 30 Caldwell J E, Castagnoli K P, Canfell P C. Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action.  Br J Anaesth . 1988;  61 693
• 31 Atherton D P, Hunter J M. Clinical pharmacokinetics of the newer neuromuscular blocking drugs.  Clin Pharmacokinet . 1999;  36 169-189
• 32 Cook D R, Freeman J A, Lai A A. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure.  Anesth Analg . 1991;  72 145-150
• 33 Doenicke A W, Czeslick E, Moss J, Hoernecke R. Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration.  Anesth Analg . 1998;  87 434-438
• 34 Schramm W M, Papousek A, Michalek-Sauberer A, Czech T, Illievich U. The cerebral and cardiovascular effects of cisatracurium and atracurium in neurosurgical patients.  Anesth Analg . 1998;  86 123-127
• 35 Kisor D F, Schmith V D, Wargin W A, Lien C A, Ornstein E, Cook D R. Importance of the organ-independent elimination of cisatracurium.  Anesth Analg . 1996;  83 1065-1071
• 36 Smith C E, van Miert M M, Parker C J, Hunter J M. A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients.  Anaesthesia . 1997;  52 833-841
• 37 Prielipp R C, Coursin D B, Scuderi P E. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients.  Anesth Analg . 1995;  81 3-12
• 38 Bryson H M, Faulds D. Cisatracurium besilate: a review of its pharmacology and clinical potential in anaesthetic practice.  Drugs . 1997;  53 848-866
• 39 Pearson A J, Harper N J, Pollard B J. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients.  Intensive Care Med . 1996;  22 694-698
• 40 Davidson J E. Neuromuscular blockade: indications, peripheral nerve stimulation, and other concurrent interventions.  New Horiz . 1994;  2 75-84
• 41 Blacher R S. On awakening paralyzed during surgery: a syndrome of traumatic neurosis.  JAMA . 1975;  234 67-68
• 42 Nielsen C H, Johnson G A. The experience of complete neuromuscular blockade in awake patients.  J Clin Anesth . 1994;  6 450
• 43 Wagner B K, Zavotsky K E, Sweeney J B, Palmeri B A, Hammond J S. Patient recall of therapeutic paralysis in a surgical critical care unit.  Pharmacotherapy . 1998;  18 358-363
• 44 Simmons L E, Riker R R, Prato B S, Fraser G L. Assessing sedation during intensive care unit mechanical ventilation with the Bispectral Index and the Sedation-Agitation Scale.  Crit Care Med . 1999;  27 1499-1504
• 45 Segredo V, Matthay M A, Sharma M L, Gruenke L D, Caldwell J E, Miller R D. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients.  Anesthesiology . 1990;  72 566-570
• 46 Engbaek J, Ostergaard D, Viby-Mogensen J, Skovgaard L T. Clinical recovery and train-of-four ratio measured mechanically and electromyographically following atracurium.  Anesthesiology . 1989;  71 391-395
• 47 Orko R, Heino A, Rosenberg P H. Vecuronium in patients with and without renal failure.  Acta Anaesthesiol Scand . 1985;  29 326-329
• 48 Miller L R, Benumof J L, Alexander L, Miller C A, Stein D. Completely absent response to peripheral nerve stimulation in an acutely hypothyroid patient.  Anesthesiology . 1989;  71 779-781
• 49 Sgalio T. Monitoring the administration of neuromuscular blockade in critical care.  Crit Care Nurs Q . 1995;  18 41-59
• 50 Brull S J, Silverman D G. Real time versus slow-motion train-of-four monitoring: a theory to explain the inaccuracy of visual assessment.  Anesth Analg. 1995;  80 548-551
• 51 Wymore M L, Eisele J H. Differential effects of d-tubocurarine on inspiratory muscles and two peripheral muscle groups in anesthetized man.  Anesthesiology . 1978;  48 360-362
• 52 Murray M J. Monitoring of peripheral nerve stimulation versus standard clinical assessment for dosing of neuromuscular blocking agents.  Crit Care Med . 1997;  25 561-562
• 53 Fernando P U, Viby-Mogensen J, Bonsu A K, Tamilarasan A, Muchhal K K, Lambourne A. Relationship between post-tetanic count and response to carinal stimulation during vecuronium-induced neuromuscular blockade.  Acta Anaesthesiol Scand . 1987;  31 593-596
• 54 Harper N J. Neuromuscular blocking drugs: practical aspects of research in the intensive care unit.  Intensive Care Med . 1993;  19 S80-S85
• 55 Bragg P, Fisher D M, Shi J. Comparison of twitch depression of the adductor pollicis and the respiratory muscles: pharmacodynamic modeling without plasma concentrations.  Anesthesiology . 1994;  80 310-319
• 56 Frankel H, Jeng J, Tilly E, St Andre A, Champion H. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit.  Am Surg . 1996;  62 503-506
• 57 Bencini A F, Houwertjes M C, Agoston S. Effects of hepatic uptake of vecuronium bromide and its putative metabolites on their neuromuscular blocking actions in the cat.  Br J Anaesth . 1985;  57 789-795
• 58 Marshall I G, Gibb A J, Durant N N. Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat.  Br J Anaesth . 1983;  55 703-714
• 59 Marik P E. Doxacurium-corticosteroid acute myopathy: another piece to the puzzle.  Crit Care Med . 1996;  24 1266-1267
• 60 Davis N A, Rodgers J E, Gonzalez E R, Fowler III A A. Prolonged weakness after cisatracurium infusion: a case report.  Crit Care Med . 1998;  26 1290-1292
• 61 Segredo V, Caldwell J E, Matthay M A, Sharma M L, Gruenke L D, Miller R D. Persistent paralysis in critically ill patients after long-term administration of vecuronium.  N Engl J Med . 1992;  327 524-528
• 62 Fischer J R, Baer R K. Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents.  Ann Pharmacother . 1996;  30 1437-1445
• 63 Leatherman J W, Fluegel W L, David W S, Davies S F, Iber C. Muscle weakness in mechanically ventilated patients with severe asthma.  Am J Respir Crit Care Med . 1996;  153 1686-1690
• 64 Giostra E, Magistris M R, Pizzolato G, Cox J, Chevrolet J C. Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide: occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination.  Chest . 1994;  106 210-220
• 65 Douglass J A, Tuxen D V, Horne M. Myopathy in severe asthma.  Am Rev Respir Dis . 1992;  146 517-519
• 66 Hansen-Flaschen J, Cowen J, Raps E C. Neuromuscular blockade in the intensive care unit: more than we bargained for.  Am Rev Respir Dis . 1993;  147 234-236
• 67 Zochodne D W, Bolton C F, Wells G A. Critical illness polyneuropathy: a complication of sepsis and multiple organ failure.  Brain . 1987;  110 819-841
• 68 Leijten F S, de Weerd W A. Critical illness polyneuropathy, facts and controversies.  J Peripher Nerv Syst . 1996;  1 28-33
• 69 Kupfer Y, Okrent D G, Twersky R A, Tessler S. Disuse atrophy in a ventilated patient with status asthmaticus receiving neuromuscular blockade.  Crit Care Med . 1987;  15 795-796
• 70 Watling S M, Dasta J F. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature.  Crit Care Med . 1994;  22 884-893
• 71 Newman P J, Quinn A C, Grounds R M. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients.  Crit Care Med . 1997;  25 1139-1142
• 72 Prielipp R C, Robinson J C, Wilson J A, MacGregor D A, Scuderi P E. Dose response, recovery, and cost of doxacurium as a continuous infusion in neurosurgical intensive care unit patients.  Crit Care Med . 1997;  25 1236-1241
• 73 de Lemos M J, Carr R R, Shalansky K F, Bevan D R, Ronco J J. Paralysis in the critically ill: intermittent bolus pancuronium compared with continuous infusion.  Crit Care Med . 1999;  27 2648-2655
• 74 MacFarlane I A, Rosenthal F D. Severe myopathy after status asthmaticus.  Lancet . 1977;  2 615
• 75 Ramsay D A, Zochodne D W, Robertson D M, Nag S, Ludwin S K. A syndrome of acute severe muscle necrosis in intensive care unit patients.  J Neuropathol Exp Neurol . 1993;  52 387-398
• 76 Sladen R N. Neuromuscular blocking agents in the intensive care unit: a two-edged sword.  Crit Care Med . 1995;  23 423-428
• 77 Op de Coul A A, Lambregts P C, Koeman J, van Puyenbroek J M, Ter Laak J H, Gabreels-Festen A A. Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation.  Clin Neurol Neurosurg . 1985;  87 17-22
• 78 Gooch J L, Suchyta M R, Balbierz J M, Petajan J H, Clemmer T P. Prolonged paralysis after treatment with neuromuscular junction blocking agents.  Crit Care Med . 1991;  19 1125-1131
• 79 Branney S W, Haenel J B, Moore F A, Tarbox B B, Schreiber R H, Moore E E. Prolonged paralysis with atracurium infusion: a case report.  Crit Care Med . 1994;  22 1699-1701
• 80 Behbehani N A, Al-Mane F, D'Yachkova Y, Pare P, FitzGerald J M. Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids.  Chest . 1999;  115 1627-1631
• 81 Larsson L, Li X, Edstrom L. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels.  Crit Care Med . 2000;  28 34-45
• 82 Rudis M I, Guslits B J, Peterson E L. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit.  Crit Care Med . 1996;  24 1749-1756
• 83 Barohn R J, Jackson C E, Rogers S J, Ridings L W, McVey A L. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.  Muscle Nerve . 1994;  17 647-654
• 84 Meyer K C, Prielipp R C, Grossman J E, Coursin D B. Prolonged weakness after infusion of atracurium in two intensive care unit patients.  Anesth Analg . 1994;  78 772-774
• 85 Faragher M W, Day B J, Dennett X. Critical care myopathy: an electrophysiological and histological study.  Muscle Nerve . 1996;  19 516-518
• 86 Massa R, Carpenter S, Holland P, Karpati G. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation.  Muscle Nerve . 1992;  15 1290-1298
• 87 DuBois D C, Almon R R. A possible role for glucocorticoids in denervation atrophy.  Muscle Nerve . 1981;  4 370-373
• 88 Panegyres P K, Squier M, Mills K R, Newsom-Davis J. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis.  J Neurol Neurosurg Psychiatry . 1993;  56 702-704
• 89 Bolton C F. Neuromuscular conditions in the intensive care unit.  Intensive Care Med . 1996;  22 841-843